Kessler Investment Group LLC increased its holdings of Pfizer Inc. (NYSE: PFE – Get Rating) stock by 7.7% during the 1st quarter, according to the company in its latest 13F filing with the Securities and Exchange Commission (SEC). ). The fund held 50,538 shares of the biopharmaceutical company after buying 3,631 additional shares during the quarter. Pfizer accounts for about 1.5% of Kessler Investment Group LLC’s portfolio, making the stock its 23rd largest position. Kessler Investment Group LLC’s holdings in Pfizer were worth $2,616,000 when it last filed with the SEC.
A number of other hedge funds also changed their positions in PFEs. Norges Bank bought a new position in Pfizer during Q4 for a value of $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company worth $715,270,000 after buying 10,440,786 additional shares in the last quarter. Coatue Management LLC bought a new position in Pfizer during Q4 worth $608,919,000. Darwin Global Management Ltd. bought a new position in Pfizer during the 4th quarter for a value of $454,553,000. Finally, State Street Corp increased its stake in Pfizer by 1.8% in the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company valued at $16,818,434,000 after buying an additional 5,013,651 shares in the last quarter. Hedge funds and other institutional investors own 66.50% of the company’s shares.
In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares in a trade that took place on Monday, May 16. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares of the company, valued at $760,732. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink. Additionally, SVP Jennifer B. Damico sold 4,218 shares in a trade that took place on Tuesday, June 7. The shares were sold at an average price of $53.96, for a total value of $227,603.28. As a result of the transaction, the senior vice president now directly owns 10,846 shares of the company, valued at approximately $585,250.16. The disclosure of this sale can be found here. Insiders sold a total of 41,126 shares of the company worth $2,075,003 in the past ninety days. 0.05% of the shares are currently held by insiders.
Several research firms have studied the PFE. SVB Leerink began covering Pfizer in a research note on Monday May 23. They set a “market performance” rating and a price target of $55.00 on the stock. StockNews.com upgraded Pfizer from a “buy” rating to a “strong buy” rating in a Tuesday, April 19 research note. Citigroup raised its price target on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a Tuesday, April 5 research note. Berenberg Bank set a price target of $50.00 on Pfizer in a Friday, May 27 research note. Finally, Morgan Stanley launched a hedge on Pfizer in a Wednesday, April 6 research note. They set an “equal weight” rating and a price target of $55.00 on the stock. Nine research analysts gave the stock a hold rating, ten gave the stock a buy rating and one gave the stock a strong buy rating. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $57.26.
NYSE PFE opened at $52.31 on Monday. The stock has a market capitalization of $293.51 billion, a price/earnings ratio of 12.00, a PEG ratio of 0.64 and a beta of 0.73. Pfizer Inc. has a 12-month low of $38.93 and a 12-month high of $61.71. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt ratio of 0.43. The stock has a 50-day moving average of $50.66 and a 200-day moving average of $52.03.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly results on Tuesday, May 3. The biopharmaceutical company reported earnings per share of $1.62 for the quarter, missing consensus analyst estimates of $1.66 per ($0.04). The company posted revenue of $25.66 billion in the quarter, versus analyst estimates of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company’s revenue for the quarter increased by 76.8% compared to the same quarter last year. During the same period a year earlier, the company posted EPS of $0.93. Stock analysts predict that Pfizer Inc. will post EPS of 6.63 for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Wednesday, June 29 will receive a dividend of $0.40. The ex-dividend date is Thursday July 28. This represents a dividend of $1.60 on an annualized basis and a yield of 3.06%. Pfizer’s payout ratio is 36.70%.
Pfizer profile (Get a rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Get Rating).
Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.